Moti­on Ett­lin (22.3859): Master plan for digi­tal trans­for­ma­ti­on in heal­th­ca­re. Use of legal stan­dards and exi­sting data

Moti­on Ett­lin (22.3859): Master plan for digi­tal trans­for­ma­ti­on in heal­th­ca­re. Use of legal stan­dards and exi­sting data

Sub­mit­ted text

(1) The Fede­ral Coun­cil is ins­truc­ted to report to par­lia­ment on the imple­men­ta­ti­on of the Moti­on Ett­lin 21.3957 “Digi­tal Trans­for­ma­ti­on in Heal­th­ca­re. Cat­ching up at last!” a con­cre­te Pre­sent a master plan that relia­bly sets out and demon­stra­tes the digi­tizati­on tar­gets in terms of time and con­tenthow they are to be achieved.

In the pro­cess of digi­tizati­on in heal­th­ca­re, the legal­ly defi­ned, uni­form stan­dards and exi­sting data­ba­ses are to be used and fur­ther deve­lo­ped, pro­vi­ded they are not pro­fit-ori­en­ted or state-supervised.

The Fede­ral Coun­cil reports annu­al­ly to Par­lia­ment on the sta­tus of the digi­tal trans­for­ma­ti­on in healthcare.

2 The Fede­ral Coun­cil is also ins­truc­ted to use the SMVS data (Swiss Medi­ci­nes Veri­fi­ca­ti­on System) for the digi­tal manage­ment of sup­p­ly shorta­ges for human medi­ci­nes and to crea­te a legal basis for this.

To ensu­re that the SMVS data set is always com­ple­te and relia­ble, the Fede­ral Coun­cil must include in the Ordi­nan­ce on Indi­vi­du­al Iden­ti­fi­ca­ti­on Marks and Safe­ty Devices on the Pack­a­ging of Medi­cinal Pro­ducts for Human Use the affixing and veri­fi­ca­ti­on of the Decla­re safe­ty fea­tures and devices man­da­to­ry – same as in the EU.

Justi­fi­ca­ti­on

1. the Moti­on Ett­lin 21.3957 “Digi­tal trans­for­ma­ti­on in heal­th­ca­re. Final­ly cat­ching up!” was unani­mously pas­sed by the Natio­nal Coun­cil and the Coun­cil of Sta­tes against the will of the Fede­ral Coun­cil. The imple­men­ta­ti­on of this moti­on must now be tack­led quick­ly, and Par­lia­ment should play a lea­ding role in this.

For a unani­mous will of the Natio­nal Coun­cil and the Coun­cil of Sta­tes is undoub­ted­ly extre­me­ly rare. If it comes about, the moti­on deser­ves abso­lu­te prio­ri­ty tre­at­ment in terms of time and con­tent. The­r­e­fo­re, the Fede­ral Coun­cil is ins­truc­ted to imme­dia­te­ly pre­sent a master plan for the imple­men­ta­ti­on of the digi­tal trans­for­ma­ti­on in heal­th­ca­re, which is to be appro­ved by SGK‑S and SGK‑N. In addi­ti­on, annu­al report­ing by the Fede­ral Coun­cil to par­lia­ment on the sta­tus of imple­men­ta­ti­on of the master plan is required.

2 The num­ber and seve­ri­ty of drug shorta­ges in Switz­er­land have been incre­a­sing for years and the situa­ti­on con­ti­nues to worsen. The FOPH report “Sup­p­ly shorta­ges of human medi­ci­nes” calls for: “In the future, the deve­lo­p­ment of a natio­nal data­ba­se is desi­ra­ble so that the cur­rent situa­ti­on regar­ding drug shorta­ges can be moni­to­red, iden­ti­fi­ed and docu­men­ted, and their cau­ses can be investigated.”

The SMVS data­ba­se was crea­ted on the basis of Artic­le 17a HMG by a non-pro­fit asso­cia­ti­on on behalf of the fede­ral govern­ment in order to increa­se the secu­ri­ty against coun­ter­feit­ing of pre­scrip­ti­on drugs in Switz­er­land. It was paid for by the indu­stry, it is orga­ni­zed as a limi­t­ed lia­bi­li­ty com­pa­ny owned by the non-pro­fit asso­cia­ti­on, and as a par­ti­cu­lar­ly important advan­ta­ge, it has a full con­nec­tion to the Euro­pean medi­ci­nes data­ba­se. This means that pre­scrip­ti­on drugs from Switz­er­land and the Euro­pean mar­ket can be veri­fi­ed for authen­ti­ci­ty in a frac­tion of a second.

With a legal basis, the data in the SMVS data­ba­se can also be used to ser­ve the FOPH, FONES and army phar­ma­cy aut­ho­ri­ties as a relia­ble plan­ning tool for anti­ci­pa­ting, iden­ti­fy­ing and mana­ging sup­p­ly gaps. It elec­tro­ni­cal­ly pro­vi­des a dai­ly updated over­view of the num­ber and avai­la­bi­li­ty of all pre­scrip­ti­on drug packa­ges in Switz­er­land. Instead of going to gre­at expen­se to crea­te a new, natio­nal data­ba­se wit­hout a con­nec­tion to the Euro­pean medi­ci­nes data­ba­se, it is finan­ci­al­ly and time-wise advan­ta­ge­ous to use the data alre­a­dy available in the SMVS database.

The con­sul­ta­ti­on on the Ordi­nan­ce on Indi­vi­du­al Iden­ti­fi­ca­ti­on Marks and Safe­ty Devices on the Pack­a­ging of Medi­cinal Pro­ducts for Human Use has been com­ple­ted. The majo­ri­ty of the par­ti­ci­pan­ts in the con­sul­ta­ti­on were in favor of the man­da­to­ry affixing and veri­fi­ca­ti­on of the safe­ty fea­tures and devices – the same as in the EU. This is the only way to ensu­re that all pre­scrip­ti­on medi­ci­nes inclu­ded in the SMVS data­ba­se are also on the Swiss market.

State­ment of the Fede­ral Coun­cil of 31.8.2022

1. the Fede­ral Coun­cil sup­ports the con­cern rai­sed by the moti­on. In order to pro­mo­te the digi­tal trans­for­ma­ti­on in heal­th­ca­re, the Fede­ral Office of Public Health (FOPH) recei­ved a man­da­te from the Fede­ral Coun­cil at the begin­ning of May 2022 to launch a pro­gram to pro­mo­te the digi­tal trans­for­ma­ti­on in heal­th­ca­re. The aim is to sub­mit a mes­sa­ge to par­lia­ment by the end of 2023, inclu­ding a cor­re­spon­ding com­mit­ment cre­dit for the imple­men­ta­ti­on of the program.

The Fede­ral Coun­cil points out that only a few legal­ly defi­ned uni­form stan­dards exist in the heal­th­ca­re sec­tor; among other rea­sons, this is becau­se the fede­ral govern­ment has only very limi­t­ed regu­la­to­ry aut­ho­ri­ty in the heal­th­ca­re sec­tor. One of the cen­tral points of the afo­re­men­tio­ned pro­gram will the­r­e­fo­re cer­tain­ly be to crea­te more bin­ding standards.

The Fede­ral Coun­cil is pre­pared to inform Par­lia­ment regu­lar­ly about the sta­tus of imple­men­ta­ti­on as part of the Commission’s work.

2 The Fede­ral Coun­cil atta­ches gre­at importance to a safe and order­ly sup­p­ly of the­ra­peu­tic pro­ducts in Switz­er­land. On Febru­ary 16, 2022, it issued a FOPH report on sup­p­ly shorta­ges of human medi­ci­nes in Switz­er­land took note of the report. It has also ins­truc­ted the FOPH and the Fede­ral Office for Natio­nal Eco­no­mic Sup­p­ly (FONES) to exami­ne the mea­su­res pro­po­sed in this report in grea­ter depth and to sub­mit a con­cre­te imple­men­ta­ti­on cata­log to the Fede­ral Coun­cil. Part of this work is also the ela­bo­ra­ti­on of a con­cre­te pro­po­sal for impro­ve­ment in the anti­ci­pa­ti­on, iden­ti­fi­ca­ti­on and manage­ment of gaps in care. The SMVS data­ba­se repres­ents a pos­si­ble opti­on here, but a com­pre­hen­si­ve ana­ly­sis is still underway.

In addi­ti­on, the eva­lua­ti­on of the con­sul­ta­ti­on on the Ordi­nan­ce on Indi­vi­du­al Iden­ti­fi­ca­ti­on Marks and Safe­ty Devices on the Pack­a­ging of Medi­cinal Pro­ducts for Human Use has not yet been com­ple­ted; it had to be deprio­ri­ti­zed due to the work on deal­ing with the Covid 19 pan­de­mic. The­re have been various cri­ti­cal voices regar­ding the man­da­to­ry affixing and veri­fi­ca­ti­on of the safe­ty fea­tures and devices. Accor­din­gly, the decis­i­on on whe­ther to imple­ment a man­da­to­ry or optio­nal solu­ti­on is still open.

The Fede­ral Coun­cil is the­r­e­fo­re of the opi­ni­on that this work should not be anti­ci­pa­ted. A decis­i­on regar­ding the pos­si­ble use of the SMVS data­ba­se can be made after the abo­ve work has been completed.

Aut­ho­ri­ty

Area

Topics

Rela­ted articles

Sub­scri­be